Human epidermal growth factor receptor-2 gene amplification in gastric cancer using tissue microarray technology

Table 1 Characteristics of patients with gastric cancer

Clinicopathological feature		Frequency n (%)
Patient age at diagnosis (yr)	Mean 69.6, min-max 27-96
Tumor diameter (cm)	Mean 4.6, min-max 1.3-12
Gender	Male	84 (70)
	Female	36 (30)
Histological type	Intestinal	80 (66.66)
	Diffuse	24 (20)
	Mixed	16 (13.33)
Tumor location	Cardia	37 (30.8)
	Corpus	39 (32.5)
	Antrum	44 (36.66)
pT stage	pT1	15 (12.5)
	pT2	65 (54.16)
	pT3-4	40 (33.33)
pN stage	pN0	36 (30)
	pN1	43 (35.8)
	pN2+3	41 (34.2)
pM stage	pM0	105 (87.5)
	pM1	15 (12.5)
Tumor grade	G1-2	42 (35)
	G3	78 (65)
Venous invasion	Present	37 (30.8)
	Absent	83 (69.2)
Lymphatic invasion	Present	84 (70)
	Absent	36 (30)
Adjuvant therapy	None	32 (26.6)
	Treated	88 (73.4)
	Chemotherapy	55 (62.5)
	Chemo/Radiotherapy	33 (37.5)
5-year survival (%)	(95% CI)	38.9 (25-52)

Table 2 Lauren phenotype, human epidermal growth factor receptor-2 immunohistochemistry and chromogenic in situ hybridization in gastric carcinoma

		Diffuse(n = 24)	Mixed(n = 16)	Intestinal(n = 80)
HER2 IHC	0	23	14	59
	1+	0	0	4
	2+	1	0	5
	3+	0	2	12
HER2 CISH	Non amplified	24	14	63
	Amplified	0	2	17

HER2: Human epidermal growth factor receptor-2; IHC: Immunohistochemistry; CISH: Chromogenic in situ hybridization.

Table 3 Comparison of human epidermal growth factor receptor-2 immunohistochemistry and chromogenic in situ hybridization in primary gastric carcinomas and matched lymph node metastases

	HER2 IHC			HER2 CISH
	PT	LNM	Concordance	PT	LNM	Concordance
Positive	7	6	85.7%	6	6	100%
Negative	38	39	97.4%	39	39	100%

HER2: Human epidermal growth factor receptor-2; IHC: Immunohistochemistry; CISH: Chromogenic in situ hybridization; PT: Primary gastric cancer; LNM: Lymph node metastases.